{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Class (Stereo):
CHEMICAL (ACHIRAL)
Nifurthiazole, a 5-nitrofuran derivative, is an antibacterial and antiprotozoal agent, it is active against Trypanosoma. It was also used for controlling Salmonella choleraesuis in swine. The mode of action of 5-nitrofuran analogues is based on red-ox biotransformation.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Uredepa, a thiotepa derivative, is a antineoplastic, alkylating agent. It has also been used experimentally as an insect chemosterilant.
Class (Stereo):
CHEMICAL (UNKNOWN)
Oxifentorex was developed as a CNS stimulant and anorectic agent. However, information about the current use of this compound is not available.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Spiroxasone is a synthetic, steroidal antimineralocorticoid of the spirolactone group patented by Merck & Co., Inc. as a diuretic and antihypertensive agent. Spiroxasone acts as potent aldosterone antagonists in animals and humans.
Status:
Investigational
Source:
INN:iometin (¹²⁵I) [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Iomethin I-125 is radioiodinated quinoline derivative with potential tumor localizing activity.
Status:
Investigational
Source:
NCT01975610: Phase 2 Interventional Completed Rheumatoid Arthritis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Spebrutinib (CC-292, AVL-292) is a selective inhibitor of BTK that was under clinical development for the treatment of rheumatoid arthritis (phase II) and B-cell Lymphoma (phase I). The drug was discovered by Avila Therapeutics, but then acquired by Celgene. Spebrutinib covalently binds to Cys 481 in BTK, blocking the ATP-binding pocket of the enzyme. The drug is no longer in Celgene's pipeline and its development is supposed to be terminated.
Status:
Investigational
Source:
NCT01314222: Phase 2 Interventional Completed Diabetic Peripheral Neuropathic Pain
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
Eur Respir J. May 1999;13(5):1144-50.: Not Applicable Human clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mirincamycin, a protein biosynthesis inhibitor was studied as an antibacterial agent. It was shown that mirincamycin could be promising candidate in the therapy and prophylaxis of multidrug-resistant falciparum malaria. Moreover, in combination with 4 or 8-aminoquinolines it could be used for the treatment and relapse prevention of vivax malaria. In addition, was studied the anti-relapse activity of mirincamycin in the Plasmodium cynomolgi sporozoite-infected Rhesus monkey model. However, the negative P. cynomolgi hypnozoite data indicates that mirincamycin is unlikely to have potential as a clinical anti-relapse agent.
Status:
Investigational
Source:
INN:iocanlidic acid (¹²³I) [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Iocanlidic Acid I-123 is a radiolabeled phenylfatty acid derivative studied as a diagnostic agent for myocardial imaging
